The Dyspepsia (Indigestion) drugs in development market research report provides comprehensive information on the therapeutics under development for Dyspepsia (Indigestion), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dyspepsia (Indigestion). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dyspepsia (Indigestion) and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Dyspepsia (Indigestion) by 14 companies/universities/institutes. The top development phase for Dyspepsia (Indigestion) is phase i with three drugs in that stage. The Dyspepsia (Indigestion) pipeline has nine drugs in development by companies and two by universities/ institutes. Some of the companies in the Dyspepsia (Indigestion) pipeline products market are: Faes Farma, Mitsubishi Tanabe Pharma and RaQualia Pharma.

The key targets in the Dyspepsia (Indigestion) pipeline products market include Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1), Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC, and Motilin Receptor (G Protein Coupled Receptor 38 or GPR38 or MLNR).

The key mechanisms of action in the Dyspepsia (Indigestion) pipeline product include Bile Acid Sequestrant with one drug in Phase II. The Dyspepsia (Indigestion) pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Dyspepsia (Indigestion) pipeline products market including Small Molecule, and Polymer.

Dyspepsia (Indigestion) overview

Indigestion is a group of gastrointestinal symptoms that occur together, including pain, a burning feeling, or discomfort in the upper abdomen; feeling full too soon while eating; and feeling uncomfortable after eating. Treatment for indigestion depends on the cause and may include medicines, changes in what you eat and drink, psychological therapies, and lifestyle changes.

For a complete picture of Dyspepsia (Indigestion)’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.